Vanguard Personalized Indexing Management LLC Purchases 314 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Vanguard Personalized Indexing Management LLC raised its position in Shockwave Medical, Inc. (NASDAQ:SWAVFree Report) by 6.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,173 shares of the company’s stock after purchasing an additional 314 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Shockwave Medical were worth $1,030,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Harbour Investments Inc. grew its stake in shares of Shockwave Medical by 3.3% in the first quarter. Harbour Investments Inc. now owns 1,300 shares of the company’s stock worth $282,000 after purchasing an additional 41 shares during the last quarter. Snowden Capital Advisors LLC grew its position in shares of Shockwave Medical by 1.4% in the 1st quarter. Snowden Capital Advisors LLC now owns 3,035 shares of the company’s stock valued at $658,000 after buying an additional 43 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Shockwave Medical by 11.5% in the third quarter. Exchange Traded Concepts LLC now owns 483 shares of the company’s stock valued at $96,000 after buying an additional 50 shares during the period. Lindbrook Capital LLC raised its position in shares of Shockwave Medical by 64.8% during the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of Shockwave Medical by 4.2% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,797 shares of the company’s stock worth $390,000 after acquiring an additional 72 shares during the period. 87.35% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Shockwave Medical

In related news, CFO Dan Puckett sold 200 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $173.88, for a total value of $34,776.00. Following the sale, the chief financial officer now owns 28,784 shares in the company, valued at approximately $5,004,961.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Dan Puckett sold 200 shares of Shockwave Medical stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $173.88, for a total transaction of $34,776.00. Following the transaction, the chief financial officer now owns 28,784 shares of the company’s stock, valued at $5,004,961.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Trinh Phung sold 1,287 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $232.18, for a total value of $298,815.66. Following the sale, the vice president now owns 32,933 shares of the company’s stock, valued at approximately $7,646,383.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,096 shares of company stock worth $10,881,425. 3.40% of the stock is owned by corporate insiders.

Shockwave Medical Trading Down 1.3 %

NASDAQ SWAV opened at $233.71 on Monday. Shockwave Medical, Inc. has a 52 week low of $157.00 and a 52 week high of $315.95. The business has a 50 day moving average price of $205.15 and a 200-day moving average price of $206.41. The company has a quick ratio of 13.19, a current ratio of 14.43 and a debt-to-equity ratio of 1.22. The company has a market cap of $8.62 billion, a price-to-earnings ratio of 36.40, a P/E/G ratio of 10.03 and a beta of 0.88.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SWAV shares. Morgan Stanley decreased their target price on shares of Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating for the company in a research report on Monday, December 4th. Leerink Partnrs restated an “outperform” rating on shares of Shockwave Medical in a report on Monday, October 16th. Needham & Company LLC lowered their price objective on Shockwave Medical from $265.00 to $260.00 and set a “buy” rating for the company in a research report on Tuesday, November 7th. Finally, SVB Leerink started coverage on Shockwave Medical in a research report on Monday, October 16th. They set an “outperform” rating and a $263.00 target price on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Shockwave Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $263.00.

View Our Latest Research Report on SWAV

Shockwave Medical Profile

(Free Report)

ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.

Featured Articles

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shockwave Medical, Inc. (NASDAQ:SWAVFree Report).

Institutional Ownership by Quarter for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.